Stock BHC BAUSCH HEALTH COMPANIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bausch Health Companies Inc. Toronto S.E.

Equities

BHC

CA0717341071

Delayed Toronto S.E.
Other stock markets
 01:33:14 2024-04-26 pm EDT 		5-day change 1st Jan Change
11.99 CAD +1.70% Intraday chart for Bausch Health Companies Inc. +0.42% +12.79%
Apr. 25 Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT
Apr. 25 Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • With a P/E ratio at 13.11 for the current year and 8.37 for next year, earnings multiples are highly attractive compared with competitors.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company does not generate enough profits, which is an alarming weak point.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BAUSCH HEALTH COMPANIES INC. Stock Bausch Health Companies Inc.
+12.79% 3.16B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.26% 653B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.69% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.50% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.93% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 233B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 201B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 193B
A+
AMGEN INC. Stock Amgen Inc.
-6.19% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BHC Stock
  4. BHC Stock
  5. Ratings Bausch Health Companies Inc.